Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-05-31

Study Completion Date

2020-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to elucidate the factors which are associated with the diagnosis and predict prognosis and therapeutic targets by collecting specimens of tissue sample, peripheral blood, and bone marrow aspirates at the time of diagnosis or relapse/refractory in patients with malignant hematologic disorders except acute leukemia. This study is eligible for patients who are diagnosed with malignant hematologic disorders except acute leukemia or who will have diagnostic procedure with suspicion of having hematologic malignancy. Prospective cohort is for patients who are not in treatment for hematologic malignancy. Retrospective cohort is for patients who are diagnosed and in treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

NCT02105168

Melanoma Non Small Cell Lung Cancer Small Cell Lung Cancer

UNKNOWN NA

Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients

NCT03079947

Diffuse Large B Cell Lymphoma Peripheral T Cell Lymphoma

UNKNOWN

Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

NCT00588198

Melanoma

COMPLETED

Biology and Genetics of Smouldering Myeloma

NCT05047107

Smouldering Myeloma MGUS Multiple Myeloma

UNKNOWN

Biomarker Research for Personalized Medicine

NCT01488591

Hematologic Neoplasms

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Hematologic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patients with malignant hematologic disorders except acute leukemia who are diagnosed pathologically according to the revised 2008 WHO classification of tumours of haematopoietic and lymphoid tissue or who will have diagnostic procedure with suspicion of having hematologic malignancy.
* Any gender and age ≥ 19 years
* Written informed consent
* Diagnosed after 2005-01-01 in retrospective cohort group.